JUNS
NASDAQ · Pharmaceuticals
Jupiter Neurosciences Inc
$2.20
+0.07 (+3.29%)
Financial Highlights (FY 2026)
Revenue
62.2K
Net Income
-24,693,391
Gross Margin
80.6%
Profit Margin
-39,655.5%
Rev Growth
-67.6%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 80.6% | 80.6% | 63.0% | 63.0% |
| Operating Margin | -40,865.7% | -36,779.2% | 30.2% | 30.1% |
| Profit Margin | -39,655.5% | -37,672.7% | 23.1% | 24.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 62.2K | 191.8K | 3.89M | 4.34M |
| Gross Profit | 50.2K | 154.6K | 2.45M | 2.74M |
| Operating Income | -25,432,353 | -70,536,572 | 1.17M | 1.31M |
| Net Income | -24,693,391 | -68,487,062 | 896.5K | 1.08M |
| Gross Margin | 80.6% | 80.6% | 63.0% | 63.0% |
| Operating Margin | -40,865.7% | -36,779.2% | 30.2% | 30.1% |
| Profit Margin | -39,655.5% | -37,672.7% | 23.1% | 24.9% |
| Rev Growth | -67.6% | -67.6% | +2.3% | +6.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 49.2K | 49.2K | 3.14M | 3.77M |
| Total Equity | 1.40M | 1.40M | 13.36M | 15.30M |
| D/E Ratio | 0.04 | 0.04 | 0.24 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -25,447,057 | -74,498,317 | 1.23M | 1.59M |
| Free Cash Flow | — | — | 754.2K | 863.0K |